Publication
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Authors not recorded
Lancet Gastroenterol Hepatol2021PMID 34358484stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerCholangiocarcinomacivic_curation1.00
- drugInfigratinibcivic_curation1.00
- geneFGFR2civic_curation1.00
- variantFGFR2 Fusioncivic_curation1.00
- variantFGFR2 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 34358484
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR2 Fusion + FGFR2 Fusion1 | ||||||||
| Infigratinib | Cholangiocarcinoma | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11230This open-label phase 2 trial included 122 patients with histologically or cytologically confirmed, locally advanced or metastatic cholangiocarcinoma, 108 of whom had an FGFR2 fusion or rearrangement.… (full text at CIViC) PMID 34358484 · Javle et al., 2021 · Open in CIViC | civic |